Royalty Pharma (RPRX) EVP Urist sells 13,684 shares in 10b5-1 planned trade
Marshall Urist, EVP of Royalty Pharma (RPRX), sold 13,684 Class A Ordinary Shares on May 20, 2026, at a weighted average price of $52.7505 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026. Following the sale, Urist directly holds 18,197 shares and indirectly owns 19,020 shares through an IRA.
Royalty Pharma EVP Urist sells $726,137 in shares By Investing.com
Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, sold 13,684 Class A Ordinary Shares for over $726,000 on May 14, 2026, through a pre-arranged trading plan. Despite the sale, which occurred near the stock's 52-week high, Royalty Pharma shares are considered undervalued by InvestingPro analysis. The company recently reported strong Q1 2026 financial performance with double-digit growth in portfolio and royalty receipts.
Royalty Pharma EVP Urist sells $726,137 in shares
Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, sold 13,684 Class A Ordinary Shares for $726,137 on May 14, 2026. This transaction was part of a pre-arranged trading plan, and Urist still holds a significant amount of shares directly and indirectly. The sale occurs as Royalty Pharma shares are near their 52-week high, following strong Q1 2026 financial results.
Royalty Pharma (RPRX) EVP sells 13,684 shares under 10b5-1 plan
Marshall Urist, EVP of Research & Investments at Royalty Pharma (RPRX), sold 13,684 Class A Ordinary Shares on May 14, 2026, at a weighted average price of $53.0647 per share. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026. After the transaction, Urist directly holds 31,881 Class A shares and indirectly holds 19,020 shares through an IRA.
Rule 10b5-1 sale by Royalty Pharma (RPRX) director Gregory Norden
Royalty Pharma director Gregory Norden executed a pre-arranged sale of 3,045 Class A Ordinary Shares at $53.00 per share on May 14, 2026, under a Rule 10b5-1 trading plan adopted in February 2026. Following this open-market transaction, Norden retains direct ownership of 191,803 Class A Ordinary Shares. The filing indicates a moderate impact and negative sentiment, typical for such pre-planned insider sales.
Royalty Pharma (Nasdaq:RPRX) - Stock Analysis
Royalty Pharma (RPRX) operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. The company recently reported strong Q1 2026 results with double-digit royalty growth, significant capital deployment into new deals, and a raised dividend. While analysts anticipate strong future growth, some risks include a high debt level and the dividend not being fully covered by free cash flows.
Royalty Pharma (NASDAQ: RPRX) Rule 144 notice for 13,684-share resale
Royalty Pharma plc (NASDAQ: RPRX) has filed a Rule 144 notice for the proposed resale of 13,684 shares of its Common Stock. The filing details an Equity Performance Award dated February 11, 2026, and a reported sale of 13,684 shares by Marshall Urist on May 14, 2026. This institutional disclosure is standard procedure for the resale of restricted securities and provides insights into insider transactions.
Royalty Pharma (RPRX) EVP gets 18,197-share equity award
Royalty Pharma plc's EVP of Research & Investments, Marshall Urist, was granted 18,197 Class A Ordinary Shares as an exempt acquisition related to the settlement of Equity Performance Awards. This transaction increased his direct holdings to 45,565 shares, with an additional 19,020 shares held indirectly through an IRA. The equity award was provided at no cash cost, aligning with Rule 16b-3 regulations for insider compensation.
[Form 4] Royalty Pharma plc Insider Trading Activity
Royalty Pharma plc EVP & CFO Terrance P. Coyne reported an exempt acquisition of 24,263 Class A Ordinary Shares on May 6, 2026, received at no cost through an affiliated entity (TPC RP EPA1 LLC) as part of Equity Performance Awards. Following this transaction, TPC RP EPA1 LLC indirectly holds 64,399 Class A Ordinary Shares. The filing details Coyne's total direct and indirect holdings, including shares held by his spouse and IRA, and additional limited partnership interests and Class E shares that are exchangeable into Class A Ordinary Shares.
Royalty Pharma Earnings: Strong Cash Flows and New Deals Support Positive Outlook and Key Readouts
Royalty Pharma reported strong first-quarter results with 10% growth in portfolio receipts and a 21% increase in adjusted EBITDA. The company also announced significant capital deployment of $528 million. This performance led management to raise their revenue guidance and prompted an increase in the fair value estimate by Morningstar analysts.
Improved Growth Outlook Prompts Fair Value Estimate Increase for Narrow-Moat Royalty Pharma
Morningstar has increased its fair value estimate for Royalty Pharma due to an improved growth outlook. The company, which is the largest buyer of biopharmaceutical royalties and a leading funder of innovation, benefits from diverse royalty streams across various therapeutic areas, setting it apart from typical biotech firms. This positive outlook is supported by strong cash flows and new deals.
Royalty Pharma plc 1Q 2026: Revenue $630.58M, EPS $0.67— 10-Q Summary
Royalty Pharma plc reported strong first-quarter 2026 financial results with revenue of $630.58 million and diluted EPS of $0.67, both showing significant increases compared to the prior-year quarter. This growth was driven by new royalty acquisitions, robust portfolio receipts from existing products, and strategic investments in new assets. The company also highlighted favorable regulatory and clinical catalysts that are expected to positively impact future cash flows.
Royalty Pharma’s Q2 2026 Dividend Raises a Deeper Question About Its Capital Allocation Strategy (RPRX)
Royalty Pharma recently announced a Q2 2026 dividend of US$0.235 per Class A ordinary share, reinforcing its focus on cash returns. The company's investment narrative is centered on reinvestment, buybacks, and royalty growth, supported by its 2026 portfolio receipts guidance of US$3,275 million to US$3,425 million. However, investors are urged to consider potential risks such as drug pricing reforms, patent pressure, and concentration risks that could impact future royalty streams.
Royalty Pharma EVP & CFO Terrance Coyne disposes of $1.73m in stock
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc (NASDAQ:RPRX), sold 34,791 Class A Ordinary Shares totaling approximately $1.73 million on April 28, 2026, through a pre-arranged 10b5-1 trading plan. These sales occurred as RPRX traded near its 52-week high after a strong 56% return over the past year. The company recently announced a quarterly dividend, partnered with Johnson & Johnson for R&D, received increased price targets from analysts, and appointed a Head of Artificial Intelligence, reflecting strategic growth and innovation.
Royalty Pharma’s Q2 2026 Dividend Raises a Deeper Question About Its Capital Allocation Strategy (RPRX)
Royalty Pharma recently declared a Q2 2026 dividend of US$0.235 per share, reinforcing its focus on cash returns alongside increased analyst optimism for upcoming earnings. This dividend, combined with positive 2026 portfolio receipts guidance, aims to signal management's confidence in funding buybacks and royalty acquisitions. However, the article suggests that investors should consider potential risks from drug pricing reforms and patent pressures despite the steady dividend.
Royalty Pharma EVP & CFO Terrance Coyne disposes of $1.73m in stock By Investing.com
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 34,791 Class A Ordinary Shares totaling approximately $1.73 million on April 28, 2026, executed via a pre-arranged 10b5-1 trading plan. The sales occurred while RPRX was near its 52-week high, and InvestingPro analysis suggests the stock might be overvalued. Despite the sale, Coyne retains substantial indirect and direct holdings, and the company recently announced a dividend, a major R&D agreement with Johnson & Johnson, and positive analyst revisions, alongside appointing a Head of AI.
Royalty Pharma EVP & CFO Terrance Coyne disposes of $1.73m in stock
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc (NASDAQ:RPRX), sold 34,791 Class A Ordinary Shares worth approximately $1.73 million on April 28, 2026. These transactions, executed via a 10b5-1 trading plan, occurred while RPRX was near its 52-week high and is considered overvalued by InvestingPro. Despite this insider sale, the company recently announced a dividend, a major R&D agreement with Johnson & Johnson, received raised price targets from analysts, and appointed a Head of AI, indicating strategic growth.
Royalty Pharma (RPRX) CFO sells 34,791 shares under 10b5-1 plan
Royalty Pharma plc EVP & CFO Terrance P. Coyne sold 34,791 Class A Ordinary Shares on April 28, 2026, at a weighted average price of $49.7784 per share. These sales were conducted through entities TPC RP EPA1 LLC and TPC RP 2021, LLC, under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025. The transaction is described as a routine liquidity event rather than an indicator of a change in corporate outlook.
Royalty Pharma Approves Dividend and Expands J&J Research Funding
Royalty Pharma (NASDAQ:RPRX) has declared a second-quarter dividend of $0.235 per share, payable on June 10, 2026. The company also announced a $500 million co-funding agreement with Johnson & Johnson for 2026 and 2027 to advance the development of JNJ-4804 for autoimmune diseases. Morgan Stanley recently increased its price target for RPRX from $61 to $63, maintaining an Overweight rating.
Royalty Pharma Declares Second Quarter 2026 Dividend
Royalty Pharma plc announced that its board of directors approved a second-quarter 2026 dividend of $0.235 per Class A ordinary share. The dividend is scheduled to be paid on June 10, 2026, to shareholders of record as of May 15, 2026. Royalty Pharma specializes in acquiring biopharmaceutical royalties and funding innovation within the biopharmaceutical industry.
Royalty Pharma will pay shareholders 23.5 cents a share on June 10
Royalty Pharma (Nasdaq: RPRX) has declared a dividend of $0.235 per Class A ordinary share for the second quarter of 2026. This dividend will be paid on June 10, 2026, to shareholders who are on record as of May 15, 2026. The company, founded in 1996, specializes in acquiring biopharmaceutical royalties and funding innovation within the biopharmaceutical industry.
Royalty Pharma (RPRX) CFO-linked entities execute planned share sales
Entities linked to Royalty Pharma's EVP & CFO, Terrance P. Coyne, sold 34,791 Class A Ordinary Shares in open-market transactions on April 1, 2026, at a weighted average price of $48.3318 per share. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025, indicating they were scheduled and not opportunistic. Despite these sales, Coyne and affiliated entities retain substantial holdings, suggesting a routine portfolio adjustment rather than a complete exit.
Royalty Pharma (RPRX) director granted 815-share equity award
Royalty Pharma plc director Bonnie L. Bassler was granted 815 Class A Ordinary Shares as an equity award, replacing a $37,500 quarterly retainer payment. The shares were issued at a reference price of $45.977 per share under the company’s 2020 Independent Director Equity Incentive Plan. Following this transaction, Bassler directly holds 73,947 Class A Ordinary Shares.
Pablo Legorreta: Pioneer of Pharmaceutical Royalties, Financial Innovator, and Founder and CEO of Royalty Pharma
Pablo Legorreta, founder and CEO of Royalty Pharma, revolutionized pharmaceutical funding by creating a model to purchase royalty streams on approved or late-stage drugs. This innovative approach provides immediate, non-dilutive capital to drug developers, accelerating medical innovation and generating significant returns for investors. Under his leadership, Royalty Pharma has become the world's largest buyer of pharmaceutical royalties, deploying over $25 billion and expanding across the entire drug development ecosystem.
Royalty Pharma EVP Coyne sells shares worth $1.58 million By Investing.com
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 34,791 Class A Ordinary Shares worth approximately $1.58 million on March 23, 2026, under a pre-arranged 10b5-1 trading plan. The shares were sold at a weighted average price of $45.5287, near Royalty Pharma's 52-week high, with InvestingPro analysis suggesting the stock is overvalued. This transaction follows other strategic moves by Royalty Pharma, including a financing agreement with Zymeworks Inc. and key appointments to bolster AI capabilities and global reach.
Royalty Pharma EVP Coyne sells shares worth $1.58 million
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 34,791 Class A Ordinary Shares for approximately $1.58 million. The sales were conducted under a pre-arranged 10b5-1 trading plan with shares trading near their 52-week high, although InvestingPro analysis suggests the stock is currently overvalued. Following these transactions, Coyne retains significant indirect and direct holdings in the company.
Royalty Pharma (RPRX) CFO’s entities sell 34,791 shares under 10b5-1 plan
Entities associated with Terrance P. Coyne, EVP & CFO of Royalty Pharma (RPRX), sold a total of 34,791 Class A Ordinary Shares on March 23, 2026, under a pre-arranged Rule 10b5-1 trading plan. The shares were sold in open-market transactions at a weighted average price of $45.5287 per share. Following these sales, the affiliated LLCs still hold significant shares in the company, and Coyne retains additional direct and indirect holdings.
RPRX SEC Filings - Royalty Pharma Plc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Royalty Pharma Plc (RPRX) SEC filings, including 10-K, 10-Q, and 8-K forms, along with insider trading reports. It details how the company, which acquires and manages royalty interests on biopharmaceutical products, discloses its financial and operational information. The platform also offers AI-powered summaries of complex sections and highlights recent insider transactions and corporate events.
RPRX SEC Filings - Royalty Pharma Plc 10-K, 10-Q, 8-K Forms
This page provides access to Royalty Pharma Plc (RPRX) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events. It details the company's royalty-based business model, capital structure, and portfolio performance, offering AI-powered summaries of complex sections. The article also highlights recent insider transactions, debt offerings, and financial results.
Royalty Pharma (RPRX) CFO linked entities sell 34,791 shares under 10b5-1 plan
Royalty Pharma's EVP and CFO, Terrance P. Coyne, reported indirect sales of 34,791 Class A ordinary shares on March 2, 2026. These transactions, executed through entities TPC RP 2021, LLC and TPC RP EPA1 LLC, were part of a pre-arranged Rule 10b5-1 trading plan adopted in August 2025. The shares were sold at weighted average prices between $46.67 and $47.01.
CFO-linked entities at Royalty Pharma (RPRX) sell 34,791 Class A shares
Entities linked to Royalty Pharma's EVP & CFO, Terrance P. Coyne, sold a total of 34,791 Class A Ordinary Shares in open-market transactions on February 23, 2026. These sales, executed at a weighted average price of $45.3165 per share, were conducted under a pre-established Rule 10b5-1 trading plan adopted in August 2025. The transactions were reported in a Form 4 SEC filing, indicating a negative sentiment for the filing's impact.
Trust-linked investor updates 5.7% Royalty Pharma (RPRX) Class A stake
R & H Trust Co. (Guernsey) Limited and Achille G. Severgnini have updated their Schedule 13D filing for Royalty Pharma plc (RPRX), reporting a combined beneficial ownership of 24,223,082 Class A shares, representing 5.7% of the outstanding Class A shares as of February 19, 2026. The filing details holdings through MGG Strategic and GG Strategic sub-funds and notes adjustments to credit facility agreements which reduced the pledged Class A shares as collateral. Although the reporting persons and various linked entities are identified, they disclaim beneficial ownership for purposes of Section 13(d) of the Securities Exchange Act.
Royalty Pharma Earnings: Resounding Receipt Growth Caps Off Landmark Year
Royalty Pharma reported strong fourth-quarter results, with portfolio receipts reaching $874 million, marking an 18% year-over-year revenue increase. The company also announced four new royalty transactions valued at up to $4.7 billion and provided fiscal 2026 guidance, projecting a 5.5% receipt growth midpoint. This performance caps off what the company described as a landmark year.
Royalty Pharma Reports Q4 and Full Year 2025 Results
Royalty Pharma (RPRX) reported strong financial performance for Q4 and full year 2025, with significant increases in Portfolio Receipts, Adjusted EBITDA, and Portfolio Cash Flow. The company deployed $2.6 billion in royalty transactions and repurchased $1.2 billion in shares, while also raising its quarterly dividend. For 2026, Royalty Pharma projects continued growth in Portfolio Receipts and anticipates pivotal study results to drive additional value.
Royalty Pharma plc SEC 10-K Report
Royalty Pharma plc has released its 2025 10-K report, detailing a year of strategic acquisitions, strong financial performance, and operational achievements, including a 5.1% increase in total income and other revenues to $2,378.2 million. The company deployed $2.6 billion in new royalties and made strategic investments, while also repurchasing 37.4 million shares. The report also outlines challenges such as market and operational risks, regulatory changes, and market fluctuations that could impact future performance.
Royalty Pharma (Nasdaq: RPRX) posts double-digit 2025 growth and issues 2026 Portfolio Receipts guidance
Royalty Pharma (NASDAQ: RPRX) announced strong financial results for 2025, with Portfolio Receipts increasing by 16% to $3,254 million and Adjusted EBITDA rising by 16% to $2,966 million. The company also provided 2026 guidance, expecting Portfolio Receipts between $3,275 million and $3,425 million, representing a 3% to 8% growth in Royalty Receipts. This performance was driven by key products and significant capital deployment into royalty transactions, alongside substantial shareholder returns through share repurchases and dividends.
Drug-royalty giant Royalty Pharma spent $2.6B and bought back 37M shares
Royalty Pharma (RPRX) reported strong financial results for Q4 and full-year 2025, with Portfolio Receipts up 18% and 16% respectively. The company deployed $2.6 billion into royalty transactions, repurchased 37 million Class A shares for $1.2 billion, and increased its quarterly dividend by 7%. Royalty Pharma also provided positive guidance for full-year 2026 Portfolio Receipts, ranging from $3,275 million to $3,425 million.
Royalty Pharma plc to Release Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
Royalty Pharma plc announced it will release its Q4 and full-year 2025 financial results on February 11, 2026, before U.S. markets open, followed by a conference call and webcast at 8:00 a.m. ET. The company, a major buyer of biopharmaceutical royalties, provides details on its website and will archive the call for 30 days. This announcement includes an AI summary, potential positives and negatives, FAQs, insider trading data, revenue figures, hedge fund activity, and analyst ratings for RPRX stock.
Royalty Pharma EVP Coyne sells $10.3 million in shares By Investing.com
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 237,531 shares of Class A Ordinary Shares between February 2nd and February 4th, 2026, totaling over $10.3 million. These transactions were executed under a 10b5-1 plan and occurred in multiple tranches at varying prices. The article also notes recent company activities including a record funding market year, a dividend increase, and an acquisition.
Royalty Pharma EVP Coyne sells $10.3 million in shares By Investing.com
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold over $10.3 million in Class A Ordinary Shares between February 2nd and February 4th, 2026, through multiple transactions ranging from $42.0839 to $43.2928 per share. These sales were executed under a 10b5-1 plan adopted in August 2025. The company also reported a record year for the royalty funding market in 2025, increased its quarterly dividend, and completed a significant acquisition of the Evrysdi royalty.
Royalty Pharma EVP Coyne sells $10.3 million in shares
Terrance P. Coyne, Executive Vice President and CFO of Royalty Pharma plc, sold over $10.3 million worth of Class A Ordinary Shares between February 2nd and February 4th, 2026. These transactions were executed under a pre-arranged 10b5-1 plan. The article also notes recent company achievements, including a record year for the royalty funding market and an increase in its quarterly dividend.
Royalty Pharma EVP Coyne sells $10.3 million in shares By Investing.com
Terrance P. Coyne, Executive Vice President and CFO of Royalty Pharma plc, sold 237,531 Class A Ordinary Shares for over $10.3 million between February 2nd and February 4th, 2026. These transactions were executed via a 10b5-1 plan and represent a significant divestiture. The company recently reported a record year for royalty funding, a dividend increase, and completed a major acquisition, leading to an analyst upgrade from UBS.
Urist Marshall, royalty pharma EVP, sells $821,810 in shares
Urist Marshall, EVP of Research & Investments at Royalty Pharma PLC, sold 20,000 Class A Ordinary Shares for approximately $821,810 on January 30, 2026. This transaction was executed under a pre-arranged 10b5-1 trading plan. Despite the sale, Royalty Pharma recently announced a record year in royalty funding, increased its quarterly dividend, and made a significant acquisition of royalty rights for the spinal muscular atrophy treatment, Evrysdi.
Urist Marshall, royalty pharma EVP, sells $821,810 in shares By Investing.com
Urist Marshall, EVP of Research & Investments at Royalty Pharma PLC, sold 20,000 Class A Ordinary Shares worth approximately $821,810 on January 30, 2026. This transaction was conducted under a pre-arranged 10b5-1 trading plan. The company recently reported a record year in royalty funding, increased its quarterly dividend, and acquired the remaining royalty on the spinal muscular atrophy treatment, Evrysdi, for $240 million upfront.
Urist Marshall, royalty pharma EVP, sells $821,810 in shares By Investing.com
Urist Marshall, Executive Vice President, Research & Investments at Royalty Pharma PLC, sold 20,000 Class A Ordinary Shares for approximately $821,810 on January 30, 2026. This sale was conducted under a pre-arranged 10b5-1 trading plan. In other news, Royalty Pharma had a record year in royalty funding in 2025, increased its quarterly dividend, and acquired PTC Therapeutics' remaining royalty on Evrysdi for $240 million upfront, prompting UBS to upgrade the stock to Buy.
Urist Marshall, royalty pharma EVP, sells $821,810 in shares
Marshall Urist, EVP at Royalty Pharma (NASDAQ:RPRX), sold 20,000 Class A Ordinary Shares for approximately $821,810 on January 30, 2026. This transaction was part of a pre-arranged trading plan. Royalty Pharma also reported a record year in royalty funding, increased its quarterly dividend, and made strategic acquisitions including a royalty on PTC Therapeutics' Evrysdi.
Royalty Pharma stock hits 52-week high at $41.71
Royalty Pharma (RPRX) stock has reached a new 52-week high of $41.71, reflecting a 31.63% appreciation over the past year. The company boasts a $24 billion market capitalization, a 2.3% dividend yield, and has consistently raised its dividend for six consecutive years. Recent strategic moves include increased market share in royalty funding, a dividend raise, and the acquisition of the remaining royalty on Evrysdi, leading UBS to upgrade the stock to "Buy."
Royalty Pharma EVP Coyne sells shares worth $2.7 million
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 69,582 Class A Ordinary Shares for approximately $2.7 million on January 20, 2026. These sales were conducted under a pre-arranged 10b5-1 trading plan. The article also highlights Royalty Pharma's strong performance in 2025, including a record $10 billion in the royalty funding market and significant acquisitions.
Royalty Pharma EVP Coyne sells shares worth $2.7 million By Investing.com
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 69,582 Class A Ordinary Shares worth approximately $2.7 million on January 20, 2026. The sales were made under a pre-arranged 10b5-1 trading plan. In other news, Royalty Pharma reported a record year for the royalty funding market in 2025 and increased its quarterly dividend.
Royalty Pharma EVP Coyne sells shares worth $2.7 million
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 69,582 Class A Ordinary Shares for approximately $2.7 million on January 20, 2026, through a pre-arranged trading plan. This transaction further details his remaining indirect and direct holdings in the company. In other news, Royalty Pharma maintained leadership in the royalty funding market in 2025, increased its quarterly dividend, and expanded its royalty interests with significant acquisitions of rights to Evrysdi and two cancer therapies.
